Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Medicine, Nephrology, Oncology +11